This breakthrough formulation utilises curcumin, a compound derived from turmeric, and offers a promising preventive measure against smoking-related diseases
Sharda University, in collaboration with Nanoved Research Foundation, has announced successful clinical trials of HARAS, a nanotechnology-based nutraceutical designed to protect smokers’ lungs by significantly reducing carbon monoxide (CO) levels. This breakthrough formulation utilises curcumin, a compound derived from turmeric, and offers a promising preventive measure against smoking-related diseases. The announcement coincides with World No Tobacco Day, underscoring the urgent need for effective interventions in smoking cessation and lung health protection.
Cigarette smoking remains a leading cause of lung cancer and other chronic diseases, with statistics showing it accounts for 90 per cent of lung cancer cases in men and 70-80 per cent in women. Smokers are 15 to 30 times more likely to develop lung cancer or succumb to it compared to non-smokers. In light of this, Dr Vijay Kanuru, Founder of Nanoved Research Foundation, have developed HARAS—a curcumin-based nutraceutical that boasts enhanced bioavailability through innovative nanotechnology.
Clinical trials, conducted by Sharda University’s esteemed researchers including Dr Deepak Bhargava, Dr Vidya Devi Chandvarkar, and Dr Mithilesh Mishra, involved 25 healthy smoker volunteers who were administered 10 ml of HARAS juice daily for 30 days. CO levels were meticulously monitored using a breath analyzer at the beginning, mid-point, and conclusion of the trial. Results revealed a statistically significant reduction in CO levels by the 30th day underscoring HARAS’s effectiveness in detoxifying smokers’ lungs. The clinical study findings are published in peer-reviewed journals International Journal of Chemical and Biochemical Sciences and the Journal of Oral and Maxillofacial Pathology.